Tumor budding as a potential prognostic marker in determining the behavior of primary liver cancers

Hepatocellular (HCC) and intrahepatic cholangiocarcinoma (ICC), the most common primary tumors of the liver, are among the most important causes of cancer deaths worldwide. Because patients with primary liver tumors are frequently diagnosed at an advanced stage and have high mortality, many efforts have been made to identify new markers to determine their behavior and treatment, similar to those in other solid organ tumors. Recently, morphological assessment of tumor budding (TB) has been revealed as a promising prognostic finding to predict tumor behavior and survival across several different tumor types. Currently, the TB score in colorectal cancer has been revealed as an important parameter in pathology report protocols to determine the course of the disease. Regarding the liver, despite enormous data showing that many mechanisms involved in TB are associated with tumor behavior in both HCC and ICC, studies focusing on the role of TB in predicting the behavior and prognosis of these tumors have started to be investigated very recently. The purpose of this review is to present data about TB in primary tumors of the liver, pointing out the potential role of this parameter in determining the course of the disease, and emphasize the need to increase the number of further studies focusing on the evaluation of this parameter with an overview of the mechanisms involved in TB.

[1]  N. Gassler,et al.  Invasion-Associated Reorganization of Laminin 332 in Oral Squamous Cell Carcinomas: The Role of the Laminin γ2 Chain in Tumor Biology, Diagnosis, and Therapy , 2022, Cancers.

[2]  S. Bonin,et al.  Tumour budding and poorly differentiated clusters in colon cancer – different manifestations of partial epithelial–mesenchymal transition , 2022, The Journal of pathology.

[3]  M. Ueno,et al.  Tumor budding may be a promising prognostic indicator in intrahepatic cholangiocarcinoma: A multicenter retrospective study , 2022, Annals of gastroenterological surgery.

[4]  Y. Akagi,et al.  Tumour Budding as an Independent Prognostic Factor for Survival in Patients With Distal Bile Duct Cancer , 2022, AntiCancer Research.

[5]  Jing Luo,et al.  Tumor budding of cervical squamous cell carcinoma: epithelial-mesenchymal transition-like cancer stem cells? , 2022, PeerJ.

[6]  C. Sigel,et al.  Prognostic Impact of Tumor Budding in Intrahepatic Cholangiocellular Carcinoma , 2022, Journal of Cancer.

[7]  Xueqin Zhao,et al.  Exosomes Regulate the Epithelial–Mesenchymal Transition in Cancer , 2022, Frontiers in Oncology.

[8]  B. Xiong,et al.  Breast Cancer Classification Based on Tumor Budding and Stem Cell-Related Signatures Facilitate Prognosis Evaluation , 2022, Frontiers in Oncology.

[9]  Fei Liu,et al.  Prognostic significance of tumor budding in biliary tract cancer. , 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  I. Nagtegaal,et al.  Refining the ITBCC tumor budding scoring system with a “zero-budding” category in colorectal cancer , 2021, Virchows Archiv.

[11]  J. Cates,et al.  Increasing Tumor Budding in Cholangiocarcinoma is Associated with Decreased Disease-Specific Survival. , 2021, Human pathology.

[12]  S. Gurzu,et al.  Subcellular Expression of Maspin in Colorectal Cancer: Friend or Foe , 2021, Cancers.

[13]  I. Nagtegaal,et al.  Tumour budding in solid cancers , 2020, Nature Reviews Clinical Oncology.

[14]  I. Zlobec,et al.  Tumour budding and its clinical implications in gastrointestinal cancers , 2020, British Journal of Cancer.

[15]  O. Helminen,et al.  Tumour budding and tumour–stroma ratio in hepatocellular carcinoma , 2020, British Journal of Cancer.

[16]  J. Merlin,et al.  SMAD4 and the TGFβ Pathway in Patients with Pancreatic Ductal Adenocarcinoma , 2020, International journal of molecular sciences.

[17]  K. Seong,et al.  The Emerging Roles of Exosomes as EMT Regulators in Cancer , 2020, Cells.

[18]  N. Kuriyama,et al.  High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection , 2020, BMC Cancer.

[19]  I. Zlobec,et al.  Tumour budding/T cell infiltrates in colorectal cancer: proposal of a novel combined score , 2020, Histopathology.

[20]  Z. Su,et al.  Crosstalk among colon cancer-derived exosomes, fibroblast-derived exosomes, and macrophage phenotypes in colon cancer metastasis. , 2020, International immunopharmacology.

[21]  A. Fassina,et al.  Tumor budding is an adverse prognostic marker in intestinal-type sinonasal adenocarcinoma and seems to be unrelated to epithelial-mesenchymal transition , 2020, Virchows Archiv.

[22]  S. Fatima,et al.  The role of tumor budding in colorectal adenocarcinoma: Possible involvement of the intestinal cancer stem cell marker Lgr5 , 2020, Indian journal of pathology & microbiology.

[23]  Laura Banias,et al.  Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition , 2019, Oncology letters.

[24]  S. Gurzu,et al.  Interaction of arylsulfatases A and B with maspin: A possible explanation for dysregulation of tumor cell metabolism and invasive potential of colorectal cancer , 2019, World journal of clinical cases.

[25]  Li Wei,et al.  A classification based on tumor budding and immune score for patients with hepatocellular carcinoma , 2019, Oncoimmunology.

[26]  Renya Zhang,et al.  Interaction between laminin-5γ2 and integrin β1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins , 2019, Oncogene.

[27]  L. Kóbori,et al.  Epithelial Mesenchymal and Endothelial Mesenchymal Transitions in Hepatocellular Carcinoma: A Review , 2019, BioMed research international.

[28]  Sean M. Hacking,et al.  Tumor Budding in Colorectal Carcinoma Showing a Paradoxical Mitotic Index (Via PHH3) With Possible Association to the Tumor Stromal Microenvironment , 2019, Applied immunohistochemistry & molecular morphology : AIMM.

[29]  K. McGlynn,et al.  The Changing Epidemiology of Primary Liver Cancer , 2019, Current Epidemiology Reports.

[30]  R. Weinberg,et al.  EMT and Cancer: More Than Meets the Eye. , 2019, Developmental cell.

[31]  Y. Nakanishi,et al.  Impact of tumour budding grade in 310 patients who underwent surgical resection for extrahepatic cholangiocarcinoma , 2019, Histopathology.

[32]  B. Nielsen,et al.  Co-Detection of miR-21 and TNF-α mRNA in Budding Cancer Cells in Colorectal Cancer , 2019, International journal of molecular sciences.

[33]  Peter D Caie,et al.  Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer , 2019, Cancer Immunology Research.

[34]  C. Blanpain,et al.  EMT Transition States during Tumor Progression and Metastasis. , 2019, Trends in cell biology.

[35]  D. Ryu,et al.  Cancer-Associated Fibroblasts and Desmoplastic Reactions Related to Cancer Invasiveness in Patients With Colorectal Cancer , 2019, Annals of coloproctology.

[36]  G. Chong,et al.  Tumor Budding is a Valuable Diagnostic Parameter in Prediction of Disease Progression of Endometrial Endometrioid Carcinoma , 2019, Pathology & Oncology Research.

[37]  B. Nielsen,et al.  miR-21 expression analysis in budding colon cancer cells by confocal slide scanning microscopy , 2018, Clinical & Experimental Metastasis.

[38]  D. Kang,et al.  Gland Attenuation, a Novel Morphological Feature of Colorectal Cancer: Evidence for an Epithelial-Mesenchymal Transition , 2018, Annals of coloproctology.

[39]  M. Kojima,et al.  The prognostic impact of differentiation at the invasive front of biliary tract cancer , 2018, Journal of surgical oncology.

[40]  L. Terracciano,et al.  Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance , 2018, Clinical Cancer Research.

[41]  F. Bray,et al.  Projections of primary liver cancer to 2030 in 30 countries worldwide , 2018, Hepatology.

[42]  I. Zlobec,et al.  Tumour budding in colorectal cancer: molecular rationale for clinical translation , 2018, Nature Reviews Cancer.

[43]  Xiangshan Fan,et al.  Heterogeneous expression of Lgr5 as a risk factor for focal invasion and distant metastasis of colorectal carcinoma , 2017, Oncotarget.

[44]  Laura Banias,et al.  Nuclear maspin expression: A biomarker for budding assessment in colorectal cancer specimens. , 2017, Pathology, research and practice.

[45]  T. Sugai,et al.  Vascular Invasion and Stromal S100A4 Expression at the Invasive Front of Colorectal Cancer are Novel Determinants and Tumor Prognostic Markers , 2017, Journal of Cancer.

[46]  E. Vassella,et al.  MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer , 2017, Modern Pathology.

[47]  Phil Quirke,et al.  Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016 , 2017, Modern Pathology.

[48]  V. Paradis,et al.  Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks. , 2017, Journal of hepatology.

[49]  Mathieu Laversanne,et al.  International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007 , 2016, International journal of cancer.

[50]  Yue-zhong Wu,et al.  Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma , 2016, Oncotarget.

[51]  H. Levine,et al.  Clinical Medicine , 1997 .

[52]  I. Zlobec,et al.  Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcome , 2016, Oncoimmunology.

[53]  C. von Buchwald,et al.  Molecular profiling of tumour budding implicates TGFβ‐mediated epithelial–mesenchymal transition as a therapeutic target in oral squamous cell carcinoma , 2015, The Journal of pathology.

[54]  Min Su,et al.  Cancer stem cells in progression of colorectal cancer , 2015, Oncotarget.

[55]  M. Risio,et al.  Tumour budding is associated with hypoxia at the advancing front of colorectal cancer , 2015, Histopathology.

[56]  I. Zlobec,et al.  Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer , 2015, British Journal of Cancer.

[57]  Hideki Ueno,et al.  Histologic Categorization of Desmoplastic Reaction: Its Relevance to the Colorectal Cancer Microenvironment and Prognosis , 2015, Annals of Surgical Oncology.

[58]  O. Schilling,et al.  Detailed analysis of epithelial‐mesenchymal transition and tumor budding identifies predictors of long‐term survival in pancreatic ductal adenocarcinoma , 2015, Journal of gastroenterology and hepatology.

[59]  M. Tschan,et al.  TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer , 2014, Oncotarget.

[60]  S. Kondo,et al.  Tropomyosin-related receptor kinase B at the invasive front and tumour cell dedifferentiation in gastric cancer , 2014, British Journal of Cancer.

[61]  I. Zlobec,et al.  Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC) , 2013, Journal of Translational Medicine.

[62]  M. Yashiro,et al.  Tumor budding and E-cadherin expression are useful predictors of nodal involvement in T1 esophageal squamous cell carcinoma. , 2013, Anticancer research.

[63]  Wun-Jae Kim,et al.  Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients , 2013, Diagnostic Pathology.

[64]  H. Ohmatsu,et al.  Characterization of the immunophenotype of the tumor budding and its prognostic implications in squamous cell carcinoma of the lung. , 2012, Lung cancer.

[65]  L. Terracciano,et al.  Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair‐proficient and ‐deficient colorectal cancers , 2011, Histopathology.

[66]  J. O’Sullivan,et al.  Epithelial-Mesenchymal Transition (EMT) Protein Expression in a Cohort of Stage II Colorectal Cancer Patients With Characterized Tumor Budding and Mismatch Repair Protein Status , 2011, International Journal of Surgical Pathology.

[67]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[68]  D. Oruzio,et al.  Tumour budding, uPA and PAI‐1 are associated with aggressive behaviour in colon cancer , 2010, Journal of surgical oncology.

[69]  A. Rustgi,et al.  The role of the miR-200 family in epithelial-mesenchymal transition , 2010, Cancer biology & therapy.

[70]  L. Terracciano,et al.  Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer , 2010, British Journal of Cancer.

[71]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[72]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[73]  C. Rubio.  Arrest of cell proliferation in budding tumor cells ahead of the invading edge of colonic carcinomas. A preliminary report. , 2008, Anticancer research.

[74]  C. Ostwald,et al.  High-degree tumor budding and podia-formation in sporadic colorectal carcinomas with K-ras gene mutations. , 2007, Human pathology.

[75]  I. Nagtegaal,et al.  Loss of membranous Ep-CAM in budding colorectal carcinoma cells , 2007, Modern Pathology.

[76]  H. Ueno,et al.  Tumor Buds Show Reduced Expression of Laminin-5 Gamma 2 Chain in DNA Mismatch Repair Deficient Colorectal Cancer , 2006, Diseases of the colon and rectum.

[77]  H. Ueno,et al.  Differential Prognostic Significance of Morphologic Invasive Markers in Colorectal Cancer: Tumor Budding and Cytoplasmic Podia , 2006, Diseases of the colon and rectum.

[78]  K. Guzińska-ustyMowiCz.  MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). , 2006, Anticancer research.

[79]  Y. Atomi,et al.  Laminin-5 gamma 2 chain and matrix metalloproteinase-2 may trigger colorectal carcinoma invasiveness through formation of budding tumor cells. , 2003, Anticancer research.

[80]  F. Bosman,et al.  Tumor cell budding and laminin‐5 expression in colorectal carcinoma can be modulated by the tissue micro‐environment , 2000, International journal of cancer.

[81]  G. Manfioletti,et al.  The expression of the high-mobility group A2 protein in colorectal cancer and surrounding fibroblasts is linked to tumor invasiveness. , 2013, Human pathology.

[82]  H. Kijima,et al.  Laminin-5γ2 chain expression is associated with tumor cell invasiveness and prognosis of lung squamous cell carcinoma. , 2012, Biomedical research.

[83]  T. Brabletz,et al.  Beta-catenin activates a coordinated expression of the proinvasive factors laminin-5 gamma2 chain and MT1-MMP in colorectal carcinomas. , 2004, International journal of cancer.

[84]  H. Bartsch,et al.  International Agency for Research on Cancer. , 1969, WHO chronicle.

[85]  Maurice B Loughreya,et al.  Dataset for pathology reporting of colorectal cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR) , 2022 .